Molecular Characteristics and Treatment Implications of <scp> <i>TP53</i> </scp> Gain‐of‐Function Mutations in Non‐Small Cell Lung Cancer
TP53 GOF mutations were associated with poorer ROS1-TKI treatment outcomes but improved immunotherapy response in NSCLC, with elevated immune activities and distinct molecular profiles.
Authors
- Degan Lu
- Qiuxiang Ou (ORCID: https://orcid.org/0000-0002-2961-2057)
- Xiaotian Zhao (ORCID: https://orcid.org/0000-0003-3823-3232)
- Xinyue Hong (ORCID: https://orcid.org/0000-0003-4674-1819)
- Feng Zhang (ORCID: https://orcid.org/0000-0002-4387-9399)
- Hua Bao (ORCID: https://orcid.org/0000-0001-5774-8755)
- Jie Min (ORCID: https://orcid.org/0000-0001-6140-4461)
- Hanlin Chen (ORCID: https://orcid.org/0000-0001-6205-3122)
- Zheng Zhao (ORCID: https://orcid.org/0000-0001-8223-3251)
- Rui Lu (ORCID: https://orcid.org/0000-0003-2177-5019)
Institutions
- Shanxi Medical University (CN)
- Wuhan University (CN)
- Shaanxi Provincial People's Hospital (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Shandong Provincial QianFoShan Hospital (CN)
- Tang Du Hospital (CN)
- Shanxi Provincial People’s Hospital (CN)
- Shandong First Medical University (CN)
- Genesee Community College (US)
- Air Force Medical University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/cam4.71215
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00